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Abstract 
Objective.  Develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). 
Methods. Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions 
using core set measures (CSM).  Myositis experts rated greater improvement among multiple pair-wise 
scenarios in conjoint analysis surveys, where different levels of improvement in two CSM were presented. 
The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined relative 
weights of CSM and conjoint analysis definitions. Performance characteristics of definitions were evaluated 
on patient profiles using expert consensus (gold standard) and were validated using a clinical trial. Nominal 
group technique was used for consensus.  
Results. Consensus was reached for a conjoint analysis–based continuous model using absolute percentage 
change in CSMs (physician, patient, and extra-muscular global activity, muscle strength, health assessment 
questionnaire and muscle enzymes). A Total Improvement Score (0-100), determined by summing scores in 
each CSM, was based on the improvement and relative weight of each CSM. Thresholds for minimal, 
moderate, and major improvement were ≥20, ≥40, and ≥60 points in the Total Improvement Score.  The 
same criteria were chosen for juvenile DM with different improvement thresholds. Sensitivity and specificity 
in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 90% and 96% for minimal, moderate, and 
major improvement, respectively. Definitions were validated in trial analysis for differentiating the physician 
rating of improvement (P<0.001).  
Conclusion.  The response criteria for adult DM/PM was the conjoint analysis model based on absolute 
percentage change in six CSMs, with thresholds for minimal, moderate, and major improvement.  
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Idiopathic inflammatory myopathies are a group of acquired, heterogeneous, systemic connective 
tissue diseases that include adult dermatomyositis (DM) and polymyositis (PM) and juvenile DM (JDM) (1). 
Despite significant morbidity and mortality associated with DM/PM, there are currently no therapies 
approved for these syndromes by the United States Food and Drug Administration or European Medicines 
Agency based on randomized controlled trials. However, with the advancement in novel therapeutics that 
target various biological pathways implicated in the pathogenesis of DM/PM (2), there is a need for well-
designed clinical trials using validated and universally accepted outcome measures. Recent clinical trials 
completed in adult DM/PM and JDM have utilized varying response criteria (3-5), again highlighting the need 
for both data- and consensus-driven criteria to be used uniformly in future studies. Core set measures (CSM) 
of myositis disease activity for adult DM/PM clinical trials have been established and validated by the 
International Myositis Assessment and Clinical Studies Group (IMACS) (6-8). They were used as the 
foundation for the current study. We undertook this study because there is a need for composite response 
criteria in myositis, given the heterogeneity of the disease and the fact that no single CSM adequately covers 
all the domains in myositis. For example, muscle enzymes can be normal in active DM, and active muscle 
weakness in DM can occur without active rash.   
Preliminary response criteria had been developed and partially validated by IMACS for adult 
DM/PM; they were based on at least 20% improvement in three of six CSM with no more than two CSM 
worse by at least 25%, with muscle strength not allowed to worsen (8;9). However, those criteria were 
considered preliminary because they were not prospectively validated. Moreover, newer methodologies, 
such as conjoint analysis, and other continuous or hybrid approaches for developing response criteria, had 
not been evaluated (10-14).  The preliminary criteria had other potential limitations, too, including equal 
weights being applied to each CSM and the lack of quantitative or continuous outcomes. With the growing 
repertoire of potential therapeutic agents, some of which may yield better results than only minimal clinical 
improvement, there is also a need to develop criteria for moderate and major clinical improvement. For 
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these reasons, and with support from the American College of Rheumatology, European League Against 
Rheumatism, IMACS, and the Paediatric Rheumatology International Trials Organization (PRINTO)(15), a 
collaboration was established to develop a data- and consensus-driven process involving multiple clinical 
datasets and the international myositis community in order to develop and validate response criteria for 
adult DM/PM and juvenile DM. This effort involved a comprehensive approach for developing candidate 
definitions for the response criteria, including continuous or hybrid definitions, using conjoint analysis 
(13;14;16-19), and for developing criteria for minimal as well as greater degrees of improvement.  This 
article focuses on the criteria for minimal and moderate improvement for adult DM/PM, whereas major 
improvement is considered preliminary. A companion article focuses on the JDM response criteria (20). 
 
 
METHODS 
Core set measures and patient profile consensus. To develop patient profiles as well as candidate 
definitions for response criteria in adult PM and DM, we used previously validated IMACS’ myositis CSM for 
patients with adult DM/PM, which include Physician and Patient Global Activity on a 10-cm Visual Analogue 
Scale (VAS), muscle strength measured by manual muscle testing (MMT), physical function measured by the 
Health Assessment Questionnaire (HAQ), Extramuscular Global Activity measured by the physician on a 10-
cm VAS, and the most abnormal serum muscle enzyme (8;21). The entire process, from the development of 
these profiles and candidate definitions through final consensus voting, is represented in the flow diagram in 
Figure 1 (22;23). Detailed methodology used to develop patient profiles, candidate definitions, validation, 
and expert consensus will be described in a separate publication (23). Briefly, real patient data from natural 
history studies and uncontrolled clinical trials were utilized to develop patient profiles, which were then 
rated by adult myositis experts to achieve consensus as to whether improvement was none, minimal, 
moderate, or major. The expert consensus of improvement was used as the gold standard to validate 
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various candidate definitions. Definite or probable criteria of Bohan and Peter classification were used to 
designate adult PM/DM (24). 
Candidate definitions of response criteria.  Six different types of candidate definitions for minimal, 
moderate, and major response (Table 1) were developed (22;25):  three types of definitions were traditional 
(categorical), and three were continuous (hybrid). Traditional definitions provide only categorical outcomes 
of minimal, moderate, and major improvement, or not improved, based on the criteria, whereas continuous 
definitions yield an improvement score as a continuous outcome measure with thresholds of minimal, 
moderate, and major improvement serving as categorical outcomes. Continuous definitions are considered 
hybrid definitions, because the same definition can be used a continuous or categorical outcome measure 
based on the study requirements. Definitions utilizing either absolute percentage change (final minus 
baseline divided by range and multiplied by 100) or relative percentage change (final minus baseline, divided 
by baseline and multiplied by 100) were evaluated as candidate definitions.  
Conjoint-analysis surveys.  Conjoint-analysis surveys were administered to myositis experts using 
1000Minds online software (11).  Experts were presented with pairs of hypothetical patient scenarios; each 
patient had different levels of improvement in the same two CSM, assuming other CSM remained the same.  
Experts rated which of the two scenarios had greater improvement. Based on the rater’s response, all other 
hypothetical patients that could be pairwise ranked were eliminated via the property of transitivity, thereby 
significantly reducing the number of scenarios presented. The PAPRIKA (Potentially All Pairwise Rankings of 
All Possible Alternatives) method determined the relative importance of the CSMs. Relative weights of CSMs 
and their levels of improvement were used to develop a scoring system by mathematical methods based on 
linear programming (13), such that when all six CSMs are considered together, the maximum score (Total 
Improvement Score) possible for representing a patient's improvement is 100 and the minimum score is 0. 
The thresholds for minimal, moderate, and major improvement in the Total Improvement Score were based 
on optimum sensitivity and specificity [using the Youden index (26)] in the subset of patient cohort data.  
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Validation of candidate response criteria. Performance characteristics of candidate criteria were 
evaluated using consensus profile ratings as the gold standard, assessing sensitivity, specificity, and area 
under the curve (AUC) to compare the performance of these candidate definitions. Those that performed 
well in the consensus profiles (sensitivity and specificity ≥ 80%, area under the curve (AUC) ≥ 0.9 for 
minimal, and AUC ≥ 0.8 for moderate and major improvement) were externally validated using data from 
adult DM/PM subjects (N=142) enrolled in the Rituximab in Myositis (RIM) trial (3). The treating physician’s 
rating of improvement (0-7 scale) at 24 weeks in the RIM trial was used for validation, and a 1-point change 
in physician rating was considered clinically significant (3). We then selected the top candidate definitions—
up to four top-performing definitions from each of the six different types of candidate definitions—for 
consideration at the final consensus conference, in order to discuss a manageable number of definitions at 
the conference.   
Consensus conference.  Nominal group technique (NGT) was applied to develop consensus among 
adult DM/PM experts regarding the top-performing candidate definitions for minimal and moderate 
improvement in adult DM/PM (27-29). Experienced moderators (Drs. Aggarwal and Miller) led the NGT 
consensus for the adult working group and the combined adult and pediatric working group (Drs. Aggarwal, 
Miller, Ruperto, and Rider). Given the paucity of data on major improvement, we considered the major 
improvement thresholds as preliminary for the final consensus meeting. For each candidate definition, the 
methodologic details used to develop them and their performance characteristics in the consensus patient 
profiles and the RIM trial were presented to the adult working group (3).  Each of the 12 participants in the 
adult working group independently reviewed the performance characteristics of all 18 top candidate 
definitions for adult DM/PM. Detailed data for each candidate definition, including sensitivity, specificity, 
and AUC, as well as kappa and odds ratio for minimal, moderate, and major improvement, were provided. 
AUC was determined from the receiver operating characteristic curve as a plot of sensitivity versus (1 – 
specificity) for Total Improvement Scores as well as for thresholds (26).   
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Adult working group.  The primary goal for the adult working group was to develop consensus 
response criteria for minimal and moderate clinical improvement for adult DM/PM based on the data 
presented, as well as the face validity, feasibility, and generalizability of the proposed candidate criteria. The 
experts in the adult working group included internationally recognized rheumatologists, neurologists, and 
dermatologists who have considerable experience in myositis and with the CSM. Voting was conducted in an 
independent, anonymous, and systematic fashion via a web-based system developed by the PRINTO 
coordinating center (30;31). In initial rounds of voting, participants were asked to rank their top five choices. 
The results were compiled, and aggregate votes and rank of each candidate definition were shared with the 
group after each round of voting. Participants were then asked in a random fashion to discuss their top- and 
bottom-ranked choices. Candidate definitions receiving a small proportion of votes were eliminated. In 
subsequent voting rounds, participants were asked to re-rank their choices after reviewing the previous 
round’s voting and discussion.  When fewer than five candidate definitions remained, each participant 
selected one as their top response criteria.  The objective was to continue the rounds of voting in the same 
manner until a single candidate definition reached consensus (≥80% of the votes) or until it was clear that 
consensus would not be reached.  
Combined adult and pediatric working group.  After consensus was achieved by each working 
group, both groups then came together to vote on a common response criteria to be used for both adult 
DM/PM and JDM (20) as the outcome measure for combined clinical trials. For this voting round, the top 
candidate definitions from the final round of voting in each working group were considered, and a similar 
online voting system and the NGT was used until consensus ≥80% was reached (27-29). For determining the 
thresholds of improvement for the selected definition, the required consensus was ≥70%, which was done 
by post-conference voting.  
 
RESULTS 
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Candidate definition for response criteria.  A total of 287 adult DM/PM candidate response criteria 
were drafted or derived using data-driven methods. Included were 10 previously published definitions, 134 
newly drafted definitions based on expert survey results, 63 weighted definitions, 68 logistic regression 
definitions, 6 conjoint analysis definitions, and 6 definitions in which differential weights were applied to the 
improvement achieved in each CSM. Among these definitions, 163 used relative percent change and 124 
used absolute percent change in CSM.  
Validation. Candidate definitions with a sensitivity and specificity ≥ 80%, AUC ≥ 0.9 for minimal, and 
AUC ≥ 0.8 for moderate and major improvement in the patient profile analysis using expert consensus rating 
as the gold standard were evaluated for external validation using the RIM clinical trial data (3) 
(Supplementary Table 1). Thus, of 122 adult DM/PM candidate definitions evaluated using the RIM trial data 
(3), 36 adult DM/PM candidate definitions, including 25 using relative and 11 using absolute percent change 
in CSM, had AUC ≥ 0.7 and showed validation in the clinical trial analysis.   
Top candidate definitions. Of 36 validated definitions, 17 top-performing adult candidate definitions 
and the top pediatric response criteria (20) were considered by the adult working group at the consensus 
conference so that, in total, 18 candidate definitions were evaluated (Table 2 and Supplementary Table 2) 
(20). They included nine categorical definitions and nine continuous definitions, in which 14 used relative 
percent change and four used absolute percent change in CSM. In each categorical definition, a patient 
would either meet or not meet the response criteria of minimal, moderate, or major improvement based on 
the degree of improvement or worsening in each CSM. In the continuous definitions, however, each subject 
generates a Total Improvement Score on a continuous scale, such that a greater degree of improvement 
corresponds to a higher score. Furthermore, patients could be categorized as achieving minimal, moderate, 
or major clinical improvement based on reaching the pre-set threshold score on the continuous scale. Table 
2 provides the performance characteristics of the top five candidate definitions for the response criteria 
selected at the consensus conference (See Supplementary Table 2 for definitions 6-18). In the patient 
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profiles, with expert consensus as the gold standard, all top candidate definitions presented at the 
conference had excellent performance characteristics, with median (interquartile range) sensitivity of 87% 
(84–90%) and specificity of 94% (92–95%) for minimal improvement with median AUC of 0.91 (0.90–0.92) 
(Table 2 and Supplementary Tables 1 and 2).  Sensitivity, specificity, and AUC were similarly high for 
moderate and major improvement criteria for these definitions (Table 2 and Supplementary Tables 1 and 2). 
All candidate definitions presented at the conference were validated using the RIM trial data at the 24-week 
time point and were shown to differentiate (P<0.001) between the treating physician’s improvement score 
at week 24 in patients rated as improved versus not improved (3) (Table 2 and Supplementary Tables 1 and 
2).  
Consensus conference voting. The top-choice definition for the adult working group, which received 
80% of the votes, was the conjoint analysis–based continuous definition model 1, which includes relative 
percent change in CSM, including physician and patient global activity, muscle strength, physical function, 
most abnormal serum enzyme level, and extra-muscular activity (Supplementary Table 3). The second-
choice definition, receiving 20% of the votes, was the conjoint analysis–based continuous model 2, which 
also includes relative percent change in CSM (Supplementary Table 3). Models 1 and 2 differ only in the 
scores associated with each level of improvement in each CSM. However, in the final round of voting and 
discussion, adult working group participants reached unanimous consensus that the response criteria for 
adult DM/PM would be identical to the top-choice response criteria for JDM, which is a conjoint analysis–
based continuous definition (model 3) using absolute percent change in CSM (Table 3) (20). Participants 
favored using the same response criteria for adult DM/PM and JDM so that data from different studies can 
be harmonized more effectively and facilitate combined trials, especially given that the definitions were 
similar with similar performance characteristics.  Moreover, the absolute percent change in CSMs (model 3) 
was thought to be more representative of meaningful clinical change than relative percent change in CSMs 
(models 1 and 2). Participants also voted to evaluate all top five candidate definitions from the adult 
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working group in future clinical trials, with the other four as secondary outcome measures.  The top three of 
these criteria, the conjoint analysis definitions, are the same for both adult DM/PM and JDM, with different 
thresholds of improvement. 
For the top conjoint-analysis, absolute percent change continuous definition (Table 3), the 
sensitivity and specificity in the patient profiles were 85% and 92% for minimal improvement, 90% and 96% 
for moderate improvement, and 92% and 98% for major improvement, respectively (Table 2). The AUC was 
0.96 for the Total Improvement Score and 0.89, 0.93, and 0.95 for minimal, moderate, and major 
improvement thresholds, respectively (Table 2). In the RIM trial (3), this response criteria showed a 
significant difference in the physician rating of improvement when the response criteria rated the patient as 
improved versus not improved for minimal, moderate, and major improvement (P<0.001) (Table 2 and 
Supplementary Table 2).  Myositis experts favored the conjoint analysis–based continuous response criteria 
because the Total Improvement Score is a continuous measure that corresponds to the magnitude of 
improvement in a patient and provides the ability to categorize a patient’s degree of improvement as 
minimal, moderate, or major (making it truly a hybrid definition). Moreover, the differential weights for 
various CSM were also thought to be congruent with an expert’s assessment of the relative importance of 
each CSM.  An important consideration in the final selection was that the top-choice definition be based on 
absolute percent change in the CSM, which was favored by the participants because, given the various visual 
analogue scale measurements used, the absolute percent change was thought to be more representative of 
meaningful clinical change.  
Combined pediatric-adult working group. Three candidate definitions were considered by the 
combined adult/pediatric working group; they included the top adult definitions (Supplementary Table 3) 
and the top pediatric definitions (20), one of which was identical in both groups. Final consensus was 
reached for the combined adult DM/PM and JDM response criteria, with 91% of participants voting for the 
conjoint analysis–based continuous definition, based on absolute percent change in the CSM (Table 3). The 
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combined working group agreed that the same final response criteria will be used for clinical trials of both 
adult DM/PM and JDM, but with different thresholds for improvement in adult versus pediatric patients as 
well as different CSM for adult (IMACS) and pediatric patients (IMACS and PRINTO). Participants favored 
using the same response criteria for adult DM/PM and JDM because the top definition from each working 
group was very similar (i.e., both being conjoint analysis–based continuous models with excellent and 
similar performance characteristics) and because it would permit comparison of outcomes in separate 
studies. Although only the IMACS CSM were used for adult DM/PM, for further congruence with pediatric 
CSM, the adult myositis experts agreed to include the Short Form-36 as a health-related quality-of-life 
measure to correspond to the PRINTO quality-of-life CSM, the parent form of the Child Health Questionnaire 
(32-34).  In a post-conference final vote, consensus (74%) was reached on threshold values for minimal, 
moderate, and major response for adult DM/PM patients, which are ≥20 in the Total Improvement Score for 
minimal improvement, ≥40 for moderate improvement, and ≥60 for major improvement. In contrast, 
consensus on the final thresholds for minimal, moderate and major response for JDM was ≥30, ≥45, and ≥70 
points, respectively.   
 
DISCUSSION  
After a systematic data- and consensus-driven process, a conjoint analysis–based continuous (i.e., 
hybrid) definition with absolute percent change in CSM was selected as the response criteria for adult 
DM/PM for minimal and moderate improvement in future clinical trials and studies (Figure 1). Because the 
total number of cases in the trial datasets and clinical profiles that achieved major improvement was small, 
it was decided that the thresholds for major improvement would be considered preliminary.  The same 
continuous (or hybrid) definition, but with different thresholds for minimal, moderate, and major 
improvement in IMACS or PRINTO CSM will be used for JDM clinical trials and studies, as well as for 
combined adult DM/PM and JDM studies and clinical trials in the future (20;23).   
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The process for developing and validating the candidate definitions for the response criteria was 
extensive and comprehensive, as we used large prospective clinical cohort datasets to develop patient 
profiles, and myositis expert consensus was used as the gold standard for clinical response. Consequently, 
we derived six different types of candidate definitions, each with many variations, leading to a total of 287 
candidate definitions tested, which were validated using natural history cohorts and a randomized clinical 
trial. Subsequently, a representative number of international myositis experts from various disciplines 
(rheumatology, neurology, and dermatology) agreed on an innovative continuous (or hybrid) model using 
absolute percent change in validated CSM.   
This response criteria was developed using a novel conjoint-analysis methodology—the 1000Minds 
software (13). Conjoint analysis, or discrete choice experiment, is a statistical technique to determine expert 
group decision-making around various measures (and multiple levels within each measure), providing the 
ability to develop differential weighting of measures and composite criteria using those measures. 
1000Minds software for conjoint analysis has been used recently to develop rheumatologic classification 
and/or outcome criteria for rheumatoid arthritis, systemic sclerosis (12;13;35;36), and gout (11;16;17;37).   
The criteria developed are continuous in nature and generate a Total Improvement Score (on a scale 
of 0–100), which can provide a quantitative degree of improvement for each subject, rather than a 
dichotomous or categorical assessment of improvement. The Total Improvement Score is the sum of the 
improvement reflected in each of the six CSM, but the individual CSM are weighted, such that those deemed 
more important provide a greater contribution to the final score. For example, changes in the MMT and 
Physician Global Disease Activity scores are weighted more heavily than changes in the most abnormal 
enzyme or HAQ. These weights were consistent with our myositis expert survey (25), which was 
independent of the process used to develop and validate our response criteria.  There are significant 
advantages of using continuous response criteria (especially in pilot studies). For example, it might be 
possible to enroll fewer subjects and still have sufficient statistical power to differentiate between 
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treatment groups by using the mean or median Total Improvement Score. Moreover, continuous measures 
have the best sensitivity to change, which allows modest treatment differences to be detected as 
statistically significant, which in turn leads to better clinical trials (10).  Moreover, the criteria developed 
provide thresholds for both minimal and moderate improvement, with a preliminary threshold for major 
improvement. Therefore, larger, adequately powered clinical trials and studies can use the threshold of 
minimal clinically significant improvement to differentiate the treatment groups, as this difference will be 
considered clinically significant. Similarly, proportions of patients achieving minimal or moderate 
improvement can be determined and compared between treatment arms. The ability of the same response 
criteria to be used not only as a continuous measure, where a higher score implies greater improvement, 
but also as a categorical response of minimal and moderate improvement, results in a unique hybrid aspect 
to this criteria. Another advantage of continuous response criteria over the previous IMACS response criteria 
is that inclusion criteria for clinical trials will not require a minimal severity in any CSM, because all levels of 
improvement in each CSM contribute more or less to the response. However, each trial will have to 
determine its own entry criteria of baseline CSM abnormality, but those will depend on the effect size, 
disease or organ target, recruitment, and feasibility—not on the response criteria alone. This is an 
improvement over the previous IMACS preliminary response criteria, where the clinical trial inclusion criteria 
required a baseline deficit of at least 20% in each CSM to enable reaching the threshold of ≥20% 
improvement in CSMs after treatment. 
Another important aspect of this response criteria is that it is based on an absolute percent change 
in CSM rather than relative percent change, as used for scoring other rheumatologic diseases, such as 
rheumatoid arthritis (38;39) and prior myositis response criteria (9). The panelists felt strongly that absolute 
percent change rather than relative percent change in CSM more accurately reflects the degree of change. 
For example, in a subject with improvement of disease activity from 2 cm to 1 cm on a 10-cm VAS, this was 
interpreted by experts as more consistent with a 10% improvement (absolute percent change) and not as 
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50% improvement reflected by relative percent change. Also, because many of the myositis CSM arbitrarily 
have zero as the lower limit of normal, using 10-cm VAS scales, the relative percent change is difficult to 
calculate if there is a change from 0 to a higher value.   
The myositis experts decided to use a common response criteria for adult DM/PM and JDM, to 
facilitate combined clinical trials, such as the RIM trial (3). Another advantage of the response criteria is that 
although it is the same for adult DM/PM and JDM, it addresses the unique differences in the CSM 
responsiveness between the two disease entities by specifying higher thresholds for JDM than for adult 
DM/PM, which reflect the fact that more responsiveness is seen in JDM patients in clinical trials (3;5). 
Additionally, the JDM response criteria allows for the possibility of using the IMACS or PRINTO CSM and 
provides a more definitive threshold for major improvement (20). 
Some limitations of the new response criteria should be noted. First, most of the CSM, although 
proven to have good reliability and validity, are subjective and evaluator dependent. However, similar 
metrics have been used successfully in rheumatoid arthritis trials, which used a physician global measure 
similar to that employed for myositis. Second, only one major clinical trial was available for validation, and it 
failed to meet its primary endpoint and was not truly placebo controlled. Thus, we validated the results 
using treating physician improvement scores in the clinical trial. Third, the threshold for major improvement 
in the response criteria is considered preliminary due to an insufficient number of adult DM/PM cases 
showing major improvement. We believe that future studies using therapeutic agents that have a greater 
impact on myositis disease activity will lead to better clinical responses, thus allowing investigators to 
determine a final threshold for major improvement. We plan to validate major improvement in future 
studies. Fourth, given that the criteria are focused on improvement and thus fail to differentiate between no 
change and worsening, these criteria might not be applicable in studies of worsening disease activity (i.e., 
disease flare designs) in myositis. However, future efforts will develop flare criteria for myositis. Fifth, the 
response criteria were developed using a PM diagnosis based on Bohan and Peter’s classification criteria, 
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but experts now recognize that PM, by those criteria, may include different syndromes, such as necrotizing 
myopathy, the anti-synthetase syndrome, and others (40;41). We believe that these response criteria will 
still be applicable to these newer entities given that the data- and consensus-driven processes used herein 
were inclusive of those syndromes. In the future, with changes in classification criteria terminology (42), the 
response criteria terminology will need to be modified accordingly. Sixth, because the criteria are complex 
and might be difficult to apply in research studies, we are developing a web-based tool as well as a 
downloadable calculator that will allow easy administration of the response criteria. The time required to 
apply these criteria is estimated to be 25 minutes to complete the CSMs at each visit (6) and 3 minutes to 
hand calculate the Total Improvement Score and degree of response, while with a computer-based system 
the calculation time is immediate.  Moreover, although the criteria may appear to be complicated, the CSM 
to be collected by any study or investigators are simple and are essentially the same as those in previous 
myositis studies and trials. Finally, patient-reported outcomes as CSMs, with the exception of HAQ and 
patient global assessment, were not part of the response criteria, perhaps due to the paucity of sensitive 
and responsive patient-reported outcomes for DM/PM (43). 
In conclusion, the development of a data- and consensus-driven conjoint analysis–based continuous 
response criteria with quantitative assessment of improvement on a scale of 0–100 and with thresholds for 
minimal, moderate, and major (preliminary threshold) improvement marks a major advancement in 
assessing response in myositis clinical trials and studies. This response criteria is sensitive and specific and 
provides a way to determine clinically meaningful change corresponding to degree of clinical improvement. 
This response criteria was valid in a clinical trial and had excellent face validity and acceptance among 
myositis experts from various specialties who care for adult DM/PM patients in different parts of the world. 
A conjoint analysis–based definition with a continuous improvement score using absolute percentage 
change in CSM with thresholds for minimal, moderate, and major improvement was selected as the 
response criteria to be used for adult clinical trials. 
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Table 1. Types of candidate definitions for response criteria that were developed and tested 
Types of candidate 
definitions of 
response 
Description Example of candidate definition for response criteria 
Previously 
published 
(categorical 
definition) 
Previously published definitions of 
improvement that were re-tested. 
MINIMAL:  3 of any 6 improved by ≥20%; no more than 2 worse by > 
25%; which cannot be MMT (9) 
MODERATE:  3 of any 6 improved by ≥50%; no more than 2 worse by > 
25%; which cannot be MMT  
MAJOR:  3 of any 6 improved by ≥70%; no more than 2 worse by > 25%; 
which cannot be MMT  
Newly drafted 
(categorical 
definition) 
Drafted relative or absolute percent change 
candidate definitions of response, based on 
recent CSM survey.  
MINIMAL:  2 of any 6 improved by ≥30%; no more than 1 worse by > 
30%; which cannot be MMT 
MODERATE:  2 of any 6 improved by ≥50%; no more than 1 worse by > 
30%; which cannot be MMT 
MAJOR:  2 of any 6 improved by ≥75%; no more than 1 worse by > 30%; 
which cannot be MMT 
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Weighted 
(categorical 
definition) 
Applied conjoint-analysis relative weights to 
CSM in newly drafted definitions. Each CSM 
receives Improvement Points (corresponding 
relative weights), when it reaches the 
threshold for minimal, moderate, or major 
improvement.  Worsening Points are applied 
similarly. Improvement is calculated based 
on a total score of improvement versus 
worsening. 
Improvement = at least 2.5 Total Improvement Points out of a maximum 
possible score of 8, and no more than 2.5 Worsening Points, where MD 
Global = 1.5 points; Patient Global = 1 point; MMT = 2 points; HAQ = 1.5 
points, ExtraMusc = 1.5 points, Enzyme = 0.5 point 
 
MINIMAL:  Improvement Points given when CSM ≥30%; Worsening 
Points given when CSM worse by >25% 
MODERATE:   Improvement Points given when CSM ≥50%; Worsening 
Points given when CSM worse by >25% 
MAJOR:   Improvement Points given when CSM ≥75%; Worsening Points 
given when CSM worse by >25% 
Logistic regression 
(continuous 
definition) 
Model of improvement using combination of 
CSM with different weights, as developed in 
the logistic regression model and rounded 
for better feasibility.  Total scores derived, 
with different cutoffs, for minimal, 
moderate, and major improvement 
Improvement Score = 5X(MD Global % change) + 3X(Patient Global % 
change) + (MMT % change) + 2X(HAQ % change) + 2X(ExtraMusc % 
change) + 2.5X(Enzyme % change) 
 
MINIMAL:  Improvement Score ≥250 
MODERATE:  Improvement Score ≥500 
MAJOR:  Improvement Score ≥750 
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Core set measure-
weighted  
(continuous 
definition) 
Multiply the percentage change in each CSM 
by the weights derived from conjoint 
analysis. Then sum (percent change in each 
CSM x conjoint analysis weights) to get final 
Total Improvement Score.  Different 
thresholds for minimal, moderate, and major 
improvement established based on 
consensus profile ratings as gold standard. 
Improvement Score = 2X (MD Global % change) + (Patient Global % 
change) + 3X (MMT % change) + 1.5X (HAQ % change) + 1.5X 
(ExtraMusc % change) + (Enzyme % change)       
 
MINIMAL:  Improvement Score ≥100 
MODERATE:  Improvement Score ≥250                                             
MAJOR:  Improvement Score ≥400 
Conjoint analysis 
(continuous 
definition) 
For a given range in the level of 
improvement in each CSM, a score is 
assigned, as developed by the conjoint-
analysis survey results and modeling.  
Greater degrees of improvement receive 
higher scores. A patient is minimally 
improved if their Improvement Score is 
above the cutoff for minimal improvement; 
similarly, for moderate and major 
improvement.  
The full model is shown in Table 3, but here are the cut points for the 
adult DM/PM model:     
 
MINIMAL:  Improvement Score ≥20 
MODERATE:  Improvement Score ≥40 
MAJOR:  Improvement Score ≥60  
 
  
Abbreviations: MINIMAL, minimal improvement; MMT, manual muscle testing; MODERATE, moderate improvement; MAJOR, major 
improvement; CSM, core set measure; MD Global, Physician Global Activity; Patient Global, Patient’s Global Activity Score; HAQ, Health 
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Assessment Questionnaire; ExtraMusc, Extramuscular Global Activity; Enzyme, most abnormal serum muscle enzyme value among aldolase, 
alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase; DM, dermatomyositis; PM, polymyositis. 
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Table 2. Detailed performance characteristics of patient profiles and clinical trial data of the top 5 candidate response criteria definition 
presented at the consensus conference* 
  
Profiles (N=270)† 
 
RIM Trial (N=147)‡  
Candidate 
definition for 
response 
criteria 
Improvement  
Sensitivity 
(%) 
Specificity 
(%) 
Threshold 
AUC 
Total 
AUC 
Candidate 
definition, 
improved 
physician 
rating§ 
Candidate 
definition, not 
improved 
physician 
rating§ 
P value Rank 
Conjoint 
analysis 
absolute % 
change 
(model 3)‖ 
Minimal: 
Improvement 
Score ≥20 
85 92 0.89 0.96 2.0 4.0 <0.001 
1 
Moderate: 
Improvement 
Score ≥40 
90 96 0.93 0.99 2.0 3.0 <0.001 
Major: Total 
Improvement 
Score ≥60 
92 98 0.95 1.00 2.0 3.0 <0.001 
Conjoint 
analysis 
Minimal: 
Improvement 
Score ≥33 
94 90 0.92 0.98 2.0 4.0 <0.001 2 
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relative % 
change 
(model 1)¶ 
Moderate: 
Improvement 
Score ≥55 
93 93 0.93 0.99 2.0 3.0 <0.001 
Major: 
Improvement 
Score ≥70 
100 95 0.97 0.99 2.0 3.0 <0.001 
Conjoint 
analysis 
relative % 
change 
(model 2)¶ 
Minimal: 
Improvement 
Score ≥30 
94 92 0.93 0.98 2.0 4.0 <0.001 
3 
Moderate: 
Total 
Improvement 
Score ≥45 
94 88 0.91 0.98 2.0 3.0 <0.001 
Major: 
Improvement 
Score ≥65 
100 98 0.99 1.00 2.0 3.0 <0.001 
Weighted 
core set 
measure 
relative % 
change# 
Minimal: 
Improvement 
Score ≥100 
92 91 0.91 0.97 2.0 3.0 <0.001 
4 
Moderate: 
Improvement 
Score ≥250 
94 91 0.93 0.98 2.0 3.0 <0.001 
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Major: 
Improvement 
Score ≥400 
100 94 0.97 1.00 2.0 3.0 <0.001 
Logistic 
regression 
relative % 
change** 
Minimal: 
Improvement 
Score ≥75 
89 93 0.91 0.97 2.0 3.0 <0.001 
5 
Moderate: 
Improvement 
Score ≥150 
94 88 0.91 0.98 2.0 3.0 <0.001 
Major: 
Improvement 
Score ≥300 
100 96 0.98 1.00 2.0 3.0 <0.001 
Abbreviations:  %, percentage; Threshold AUC, area under the curve, calculated as the AUC from the receiver operating characteristic curve for 
the Total Improvement Score and the threshold for minimal, moderate, and major improvement; Total AUC, calculated as the AUC from the 
receiver operating characteristic curve, using the Total Improvement Score and the threshold cutoffs for minimal, moderate, and major 
improvement, which applies only to continuous definitions; Minimal, minimal improvement; Moderate, moderate improvement; Major, major 
improvement; N/A, not applicable.  
*Supplementary Table 2 presents definitions 6-18 from the consensus conference ratings. 
†The reference standard for sensitivity and specificity was myositis expert consensus rating of improvement. 
‡RIM trial, Rituximab in Myositis clinical trial (3). 
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§Physician rating: Treating physician’s rating on a Likert scale of 1-7, where lower scores represent a greater degree of improvement, at week 24 
of the Rituximab in Myositis clinical trial (3). Comparison of median rating when the candidate response criteria definition was improved versus 
not improved. A 1-point difference in physician rating of improvement from no improvement to minimal improvement was considered not just 
statistically significant, but also was clinically significant. 
‖Conjoint analysis–based continuous candidate response criteria using absolute percentage change in core set measures (absolute percentage 
change model) is presented in Table 3.  This criteria is also the top response criteria for juvenile dermatomyositis, but with different thresholds 
in the Total Improvement Score for minimal, moderate and major improvement (20). 
¶Conjoint analysis–based continuous candidate definitions using relative percentage change in core set measures are presented in 
Supplementary Table 3. These criteria are also the second and third choice criteria for juvenile dermatomyositis, but with different thresholds in 
the Total Improvement Score for minimal, moderate and major improvement (20). 
#Total Improvement Score = 2X(MD Global % change) + (Patient Global % change) + 3X(MMT % change) + 1.5X(HAQ % change) + 1.5X(ExtraMusc 
% change) + (Enzyme % change) 
**Total Improvement Score = (MD Global % change) + (Patient Global % change) + (MMT % change) + (HAQ % change) + (ExtraMusc % change) + 
(Enzyme % change) 
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Table 3. Final myositis response criteria (conjoint analysis model 3) for 
minimal, moderate, and major improvement in adult DM/PM and combined 
adult DM/PM and JDM clinical trials and studies 
Conjoint analysis–based continuous response criteria using absolute 
percentage change in core set measures 
Core set measure Level of improvement Level score 
Physician Global Activity 
Worsening to 5% improvement 0 
>5% to 15% improvement 7.5 
>15% to 25% improvement 15 
>25% to 40% improvement 17.5 
>40% improvement 20 
Patient Global Activity 
Worsening to 5% improvement 0 
>5% to 15% improvement 2.5 
>15% to 25% improvement 5 
>25% to 40% improvement 7.5 
>40% improvement 10 
Manual muscle testing 
(MMT) 
Worsening to 2% improvement 0 
>2% to 10% improvement 10 
>10% to 20% improvement 20 
>20% to 30% improvement 27.5 
>30% improvement 32.5 
Health Assessment 
Questionnaire (HAQ) 
Worsening to 5% improvement 0 
>5% to 15% improvement 5 
>15% to 25% improvement 7.5 
>25% to 40% improvement 7.5 
>40% improvement 10 
Enzyme (most abnormal) 
Worsening to 5% improvement 0 
>5% to 15% improvement 2.5 
>15% to 25% improvement 5 
>25% to 40% improvement 7.5 
>40% improvement 7.5 
Extra muscular activity 
Worsening to 5% improvement 0 
>5% to 15% improvement 7.5 
 34 
 
>15% to 25% improvement 12.5 
>25% to 40% improvement 15 
>40% improvement 20 
  Improvement category 
Total 
Improvement 
Score* 
Adult DM/PM thresholds  
Minimal ≥ 20 
Moderate ≥ 40 
Major ≥ 60 
JDM thresholds  
Minimal ≥ 30 
Moderate ≥ 45 
Major ≥ 70 
 
Abbreviations:  DM, dermatomyositis; PM, polymyositis; JDM, juvenile dermatomyositis; Enzyme, most 
abnormal serum muscle enzyme level among creatine kinase, aldolase, alanine transaminase, aspartate 
aminotransferase, and lactate dehydrogenase.  
* Note that this response criteria is also proposed for use in combined adult DM/PM and JDM clinical trials 
(20).  For comparison, the thresholds of improvement in the Total Improvement Score for JDM are ≥ 30 for 
minimal, ≥ 45 for moderate, and ≥ 70 for major improvement. Also note that the criteria for major 
improvement for adult DM/PM are preliminary. 
How to calculate the improvement score:  the absolute percentage change (final value – baseline value / 
range) X 100 is calculated for each core set measure. For muscle enzymes, the most abnormal enzyme at 
baseline is used.  The enzyme range was calculated based on 90% range of enzymes from natural history 
data (32;44), and for creatine kinase is 15 times the upper limit of normal; for aldolase is 6 times the upper 
limit of normal, and for lactate dehydrogenase, aspartate aminotransferase, and alanine transaminase is 3 
times the upper limit of normal.  Upper limit of normal is as per the individual laboratory participating in the 
center. Range for Physician Global, Patient Global, MMT, HAQ, and Extramuscular Global Activity are based 
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on the instrument scale used in the trial. An improvement score is assigned for each core set measure based 
on the absolute percentage change in core set measure as per the definition. These individual core set 
measure improvement scores are then totaled among the six core set measures to give the Total 
Improvement Score.  The thresholds for minimal, moderate, and major improvement are provided.  The 
Total Improvement Score itself may also be compared among treatment arms in a trial.  A Total 
Improvement Score between 0–100 also corresponds to the degree of improvement, with higher 
improvement scores corresponding to a greater degree of improvement.
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Supplementary Table 1. Summary of performance characteristics of the 18 top candidate response criteria definitions evaluated at the 
consensus conference, based on patient profiles as well as clinical trial data 
    Profiles (N=270) RIM Trial (N=147) 
Improvement 
category 
Improved 
N (%) 
Sensitivity 
(%) 
Median 
(IQR) 
Specificity 
(%) 
Median 
(IQR) 
Threshold 
AUC 
Median 
(IQR) 
Total 
Improvement 
Score AUC 
Median (IQR) 
Median (IQR) 
physician 
rating* when 
definition 
improved 
Median 
(IQR) 
physician 
rating* 
when 
definition 
NOT 
improved 
Median P value 
(IQR) 
Minimal 157 (64) 
87 
(84 - 90) 
94 
(92 - 95) 
0.91 
(0.90 - 0.92) 
0.97 
(0.96 - 0.98) 
2.0 
(2.0 - 2.0) 
3.0 
(3.0 - 4.0) 
<0.001 
(<0.001 - <0.001) 
Moderate 72 (31) 
91 
(85 - 93) 
91 
(86 - 95) 
0.90 
(0.87 - 0.91) 
0.98 
(0.97 - 0.98) 
2.0 
(2.0 - 2.0) 
3.0 
(3.0 - 3.0) 
<0.001 
(<0.001 - <0.001) 
Major 12 (5) 
100 
(92 - 100) 
95 
(92 - 96) 
0.95 
(0.93 - 0.97) 
1.00 
(0.99 - 1.00) 
2.0 
(2.0 - 2.0) 
3.0 
(3.0 - 3.0) 
<0.001 
(<0.001 - <0.001) 
 
Abbreviations: RIM trial, Rituximab in Myositis clinical trial; IQR, interquartile range; Threshold AUC, area under the curve, calculated as the AUC 
from the receiver operating characteristic curve for the Total Improvement Score and the threshold for minimal, moderate, and major 
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improvement; Total Improvement Score AUC, calculated as the AUC from the receiver operating characteristic curve, using the Total 
Improvement Score and the threshold cutoffs for minimal, moderate, and major improvement, which applies only to continuous definitions. 
*The reference standard for sensitivity and specificity was myositis expert consensus rating of improvement. Physician rating: Treating physician 
rating on a Likert scale of 1-7, where a lower score represents a greater degree of improvement, at week 24 of the Rituximab in Myositis clinical 
trial (3). Comparison of median rating when candidate definition was improved versus not improved.  A 1-point difference in physician rating of 
improvement from no improvement to minimal improvement was considered not just statistically significant but also was clinically significant. 
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Supplementary Table 2. Detailed performance characteristics of patient profiles and clinical trial data of the candidate definitions ranked 6–18, 
presented at the consensus conference  
  
Profiles (N=270)* 
 
RIM Trial (N=147)†  
Candidate 
definition 
for 
response 
criteria 
Improvement category 
Sensitivity 
(%) 
Specificity 
(%) 
Threshold 
AUC 
Total 
AUC 
Candidate 
definition, 
improved 
physician 
rating‡ 
Candidate 
definition, not 
improved 
physician 
rating‡ 
P value Rank 
Weighted 
core set 
measure 
relative % 
change§ 
Minimal: Improvement 
Score ≥150 
86 94 0.90 0.97 2.0 3.0 <0.001 
6 
Moderate: 
Improvement Score 
≥300 
89 93 0.91 0.97 2.0 3.0 <0.001 
Major: Improvement 
Score ≥450 
100 96 0.98 1.00 2.0 3.0 <0.001 
Logistic 
regression 
absolute 
% 
change§§‖ 
Minimal: Improvement 
Score ≥10 
93 92 0.93 0.98 2.0 4.0 <0.001 
7 
Moderate: 
Improvement Score 
≥40 
85 95 0.90 0.97 2.0 3.0 <0.001 
Major: Improvement 
Score ≥80 
92 97 0.95 0.99 2.0 3.0 <0.001 
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Newly 
drafted 
definition 
 relative 
% change 
Minimal: 2 of any 6 
improved by ≥30%; no 
more than 1 worse by 
> 30%, which cannot 
be MMT 
88 93 0.91  N/A 2.0 3.0 <0.001 
8 
Moderate: 2 of any 6 
improved by ≥50%; no 
more than 1 worse by 
> 30%, which cannot 
be MMT 
90 84 0.87 N/A 2.0 3.0 <0.001 
Major: 2 of any 6 
improved by ≥75%; no 
more than 1 worse by 
> 30%, which cannot 
be MMT 
100 87 0.94 N/A  2.0 3.0 <0.001 
Logistic 
regression 
absolute 
% 
change¶ 
Minimal: Improvement 
Score ≥10 
83 95 0.89 0.96 2.0 4.0 <0.001 
9 
Moderate: 
Improvement Score 
≥25 
83 92 0.88 0.96 2.0 3.0 <0.001 
Major: Improvement 
Score ≥50 
92 94 0.93 0.98 2.0 3.0 <0.001 
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Weighted 
definition 
relative % 
change# 
Minimal:  
Improvement Points 
given when CSM 
≥20%; Worsening 
Points given when 
CSM worse by >25% 
90 94 0.92 N/A  2.0 3.0 <0.001 
10 
Moderate: 
Improvement Points 
given when CSM 
≥30%; Worsening 
Points given when 
CSM worse by >25% 
97 77 0.87 N/A 2.0 3.0 <0.001 
Major: Improvement 
Points given when 
CSM ≥70%; Worsening 
Points given when 
CSM worse by >25% 
83 88 0.85 N/A  1.0 3.0 <0.001 
Logistic 
regression 
relative % 
change** 
Minimal: Improvement 
Score ≥250 
85 92 0.88 0.95 2.0 3.0 <0.001 
11 Moderate: 
Improvement Score 
≥500 
92 86 0.89 0.97 2.0 3.0 <0.001 
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Major: Improvement 
Score ≥750 
100 92 0.96 0.99 2.0 3.0 <0.001 
Weighted 
definition 
relative % 
change†† 
Minimal: Improvement 
Points given when 
CSM≥30%; Worsening 
Points given when 
CSM worse by >25% 
88 93 0.91 N/A  2.0 3.0 <0.001 
12 
Moderate: 
Improvement Points 
given when CSM≥50%; 
Worsening Points 
given when CSM 
worse by >25% 
92 81 0.87 N/A 2.0 3.0 <0.001 
Major: Improvement 
Points given when 
CSM≥75%; Worsening 
Points given when 
CSM worse by >25% 
100 86 0.93  N/A 2.0 3.0 <0.001 
Previously 
published 
relative % 
change 
Minimal:  3 of any 6 
improved by ≥15%; no 
more than 1 worse by 
> 25%, which cannot 
be MMT (9) 
89 95 0.92 N/A  2.0 3.0 <0.001 13 
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Moderate:  3 of any 6 
improved by ≥30%; no 
more than 1 worse by 
> 25%, which cannot 
be MMT 
92 91 0.92 N/A 2.0 3.0 <0.001 
Major:  3 of any 6 
improved by ≥60%; no 
more than 1 worse by 
> 25%, which cannot 
be MMT 
100 92 0.96 N/A  2.0 3.0 <0.001 
Weighted 
definition 
relative % 
change‡‡ 
Minimal:  
Improvement Points 
given when CSM 
≥30%; Worsening 
Points given when 
CSM worse by >25% 
87 94 0.91 N/A  2.0 3.0 <0.001 
14 
Moderate: 
Improvement Points 
given when CSM 
≥50%; Worsening 
Points given when 
CSM worse by >25% 
85 81 0.83 N/A 2.0 3.0 <0.001 
Major: Improvement 
Points given when 
83 88 0.85 N/A  1.5 3.0 <0.001 
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CSM ≥75%; Worsening 
Points given when 
CSM worse by >25% 
Previously 
published 
relative % 
change 
Minimal:  3 of any 6 
improved by ≥20%; no 
more than 2 worse by 
> 25%, which cannot 
be (9) 
84 97 0.90 N/A  2.0 3.0 <0.001 
15 
Moderate:  3 of any 6 
improved by ≥30%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
92 89 0.91 N/A 2.0 3.0 <0.001 
Major:  3 of any 6 
improved by ≥60%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
100 92 0.96  N/A 2.0 3.0 <0.001 
Previously 
published 
relative % 
change 
Minimal:  3 of any 6 
improved by ≥20%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT (9) 
84 97 0.90  N/A 2.0 3.0 <0.001 16 
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Moderate:  3 of any 6 
improved by ≥50%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT (9) 
67 98 0.82 N/A 2.0 3.0 <0.001 
Major:  3 of any 6 
improved by ≥70%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
83 96 0.90  N/A 1.5 3.0 <0.001 
Newly 
drafted 
definition 
 relative 
% change 
Minimal:  4 of any 6 
improved by ≥5%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
83 98 0.90  N/A 2.0 4.0 <0.001 
17 
Moderate:  4 of any 6 
improved by ≥25%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
81 98 0.89 N/A 2.0 3.0 <0.001 
Major:  4 of any 6 
improved by ≥50%; no 
more than 2 worse by 
92 96 0.94  N/A 2.0 3.0 <0.001 
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> 25%, which cannot 
be MMT 
Newly 
drafted 
definition 
 absolute 
% change 
Minimal:  4 of any 6 
improved by ≥2%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
83 97 0.90  N/A 2.0 4.0 <0.001 
18 
Moderate:  4 of any 6 
improved by ≥10%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
82 99 0.91 N/A 2.0 3.0 <0.001 
Major:  4 of any 6 
improved by ≥20%; no 
more than 2 worse by 
> 25%, which cannot 
be MMT 
100 97 0.99  N/A 2.0 3.0 <0.001 
 
Abbreviations: %, percentage; Threshold AUC, area under the curve, calculated as the AUC from the receiver operating characteristic curve for 
the Total Improvement Score (Total AUC) and the threshold for minimal, moderate, and major improvement; Total AUC, calculated as the AUC 
from the receiver operating characteristic curve, using the Total Improvement Score and the threshold cutoffs for minimal, moderate, and major 
improvement, which applies only to continuous definitions; Minimal, minimal improvement; Moderate, moderate improvement; Major, major 
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improvement; MMT, manual muscle testing; CSM, core set measures; MD Global, Physician Global Activity; Patient Global, Patient’s Global 
Activity Score; HAQ, Health Assessment Questionnaire; ExtraMusc, Extramuscular Global Activity; Enzyme, most abnormal serum muscle enzyme 
value; CSM, core set measure.  
*The reference standard for sensitivity and specificity was myositis expert consensus rating of improvement. 
† RIM trial, Rituximab in Myositis clinical trial (3). 
‡ Physician rating: Treating physician’s rating on a Likert scale of 1-7, where lower scores represent a greater degree of improvement, at week 24 
of the Rituximab in Myositis clinical trial (3). Comparison of median rating when the candidate response criteria definition was improved versus 
not improved. A 1-point difference in physician rating of improvement from no improvement to minimal improvement was considered not just 
statistically significant, but also was clinically significant. 
 
§Total Improvement Score = 2X(MD Global % change) + (Patient Global % change) + 3.5X(MMT % change) + (HAQ % change) + 2X(ExtraMusc % 
change) + (Enzyme % change) 
 
‖§§ Total Improvement Score = (MD Global % change) + (MMT % change) + (HAQ % change) + (ExtraMusc % change) 
 
¶ Total Improvement Score = (MD Global % change) + 0.5X(Patient Global % change) + 0.5X(ExtraMusc % change) 
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# Improvement = at least 2.4 Improvement Points of 8 Total Improvement Points, and no more than 1.6 Worsening Points, where MD Global = 
1.5 points, Patient Global = 1 point, MMT = 2 points, HAQ = 1.5 points, ExtraMusc = 1.5 points, Enzyme = 0.5 point 
 
** Total Improvement Score = 5X(MD Global % change) + 3X(Patient Global % change) + (MMT % change) + 2X(HAQ % change) + 2X(ExtraMusc % 
change) + 2.5X(Enzyme % change) 
 
†† Improvement = at least 2.5 Improvement Points of 8 Total Improvement Points, and no more than 2.5 Worsening Points, where MD Global = 2 
points, Patient Global = 1 point, MMT = 3 points, HAQ = 1.5 points, ExtraMusc = 1.5 points, Enzyme = 1 point 
 
‡‡ Improvement = at least 2.5 Improvement Points of 8 Total Improvement Points, and no more than 2.5 Worsening Points, cwhere MD Global = 
1.5 points, Patient Global = 1 point, MMT = 2 points, HAQ = 1.5 points, ExtraMusc = 1.5 points, Enzyme = 0.5 point 
  
 48 
 
Supplementary Table 3. Conjoint analysis relative percentage change candidate definitions for response criteria*  
  
Conjoint analysis–based continuous candidate 
definitions using relative percentage change in 
core set measures (model 1)   
Conjoint analysis–based continuous candidate 
definitions using relative percentage change in 
core set measures (model 2) 
Core set measure Level of improvement Level score   Level of improvement Level score 
Physician Global 
Activity 
Worsening to 5% improvement 0   Worsening to 5% improvement 0 
>5% to 20% improvement 7.5 
 
>5% to 25% improvement 7.5 
>20% to 40% improvement 15 
 
>25% to 50% improvement 15 
>40% to 60% improvement 20 
 
>50% to 75% improvement 17.5 
>60% improvement 25   >75% improvement 20 
Patient Global 
Activity 
Worsening to 5% improvement 0 
 
Worsening to 5% improvement 0 
>5% to 20% improvement 2.5 
 
>5% to 25% improvement 2.5 
>20% to 40% improvement 5 
 
>25% to 50% improvement 5 
>40% to 60% improvement 7.5 
 
>50% to 75% improvement 7.5 
>60% improvement 7.5   >75% improvement 10 
Manual muscle 
testing (MMT)  
Worsening to 2% improvement 0 
 
Worsening to 5% improvement 0 
>2% to 10% improvement 5 
 
>5% to 20% improvement 10 
>10% to 20% improvement 12.5 
 
>20% to 40% improvement 20 
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>20% to 30% improvement 17.5 
 
>40% to 60% improvement 27.5 
>30% improvement 22.5   >60% improvement 32.5 
Health Assessment 
Questionnaire 
(HAQ)  
Worsening to 5% improvement 0 
 
Worsening to 5% improvement 0 
>5% to 20% improvement 5 
 
>5% to 25% improvement 5 
>20% to 40% improvement 7.5 
 
>25% to 50% improvement 7.5 
>40% to 60% improvement 10 
 
>50% to 75% improvement 7.5 
>60% improvement 12.5   >75% improvement 10 
Enzyme (most 
abnormal) 
Worsening to 5% improvement 0 
 
Worsening to 5% improvement 0 
>5% to 20% improvement 5 
 
>5% to 20% improvement 2.5 
>20% to 40% improvement 10 
 
>20% to 40% improvement 5 
>40% to 60% improvement 15 
 
>40% to 60% improvement 7.5 
>60% improvement 15   >60% improvement 7.5 
Extra muscular 
activity 
Worsening to 5% improvement 0 
 
Worsening to 5% improvement 0 
>5% to 20% improvement 7.5 
 
>5% to 20% improvement 7.5 
>20% to 40% improvement 10 
 
>20% to 40% improvement 12.5 
>40% to 60% improvement 15 
 
>40% to 60% improvement 15 
>60% improvement 17.5   >60% improvement 20 
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  Improvement category 
Total 
Improvement 
Score† 
  Improvement category 
Total 
Improvement 
Score† 
Adult DM/PM 
thresholds  
Minimal ≥ 33   Minimal ≥ 30 
Moderate ≥ 55 
 
Moderate ≥ 45 
Major ≥ 70   Major ≥ 65 
JDM thresholds 
Minimal ≥ 33   Minimal ≥ 33 
Moderate ≥ 60  Moderate ≥ 55 
Major ≥ 80   Major ≥ 77 
 
Abbreviations: Enzyme, most abnormal serum muscle enzyme level among creatine kinase, aldolase, alanine transaminase, aspartate 
aminotransferase, and lactate dehydrogenase; DM, dermatomyositis; PM, polymyositis.  
*These conjoint analysis models are identical to those for juvenile DM, but with different thresholds in the Total Improvement Score for 
minimal, moderate and major improvement (20).   
 
†How to calculate the Improvement Score:  The relative percent change (final value – baseline value / baseline value) X 100 is calculated for each 
core set measure.  An Improvement Score is assigned for each core set measure based on the relative percent change of each measure. These 
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are totaled among the six core set measures to give the Total Improvement Score.  The thresholds for minimal, moderate, and major 
improvement are provided.  The Improvement Scores may also be compared among treatment arms in the trial.  
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Figure 1. Flow diagram of the entire process used to develop and validate the approved response criteria for 
adult dermatomyositis and polymyositis. 
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